Tone mix
Week by week 45 weeks
Share of Ligand Pharmaceuticals Inc.'s 116 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of May 4, 2026 · tone -100Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down After Earnings Miss-140
- Week of Jul 20, 2026 · tone +100Ligand Pharmaceuticals (NASDAQ:LGND) Earns Buy Rating from Analysts at Citigroup+90
- Week of Jun 22, 2026 · tone -100Ligand Pharmaceuticals Stock Falls 7% Over Announcement Of $550 Mln Notes Offering-80
- Week of Aug 31, 2026 · tone +100Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book+72
- Week of May 18, 2026 · tone -50Investment Analysts' Weekly Ratings Changes for Ligand Pharmaceuticals (LGND)-65
- Week of Oct 5, 2026 · tone +98Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Rating of "Buy" from Brokerages+60
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Ligand Pharmaceuticals Inc. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 2 | 0 |
| Last 30 sessions | 9 | +33 |
| Last 90 sessions | 31 | +29 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletAnalyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND) | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletLigand Pharmaceuticals (LGND) Set to Announce Earnings on ThursdayNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ligand Pharmaceuticals (LGND) Set to Announce Earnings on Thursday | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 5, 2026
2 headlines, average tone +98: 2 positive, 0 neutral and 0 negative. Showing all 2.
- www.tickerreport.com · 1 outletLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Rating of "Buy" from BrokeragesPositive
- www.themarketsdaily.com · 1 outletLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Has Consensus Price Target of $337.89 According to AnalystsPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Rating of "Buy" from Brokerages | www.tickerreport.com | 1 | Positive |
| Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Has Consensus Price Target of $337.89 According to Analysts | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 2, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletAnalysts' Weekly Ratings Updates for Ligand Pharmaceuticals (LGND)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Analysts' Weekly Ratings Updates for Ligand Pharmaceuticals (LGND) | www.dailypolitical.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, September 29, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletFinancial Review: Ligand Pharmaceuticals (NASDAQ:LGND) & Myriad Genetics (NASDAQ:MYGN)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Financial Review: Ligand Pharmaceuticals (NASDAQ:LGND) & Myriad Genetics (NASDAQ:MYGN) | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Ligand Pharmaceuticals Inc., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.